{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-016818","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.402019+00:00","generated_at":"2026-06-01T23:15:04.565565+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Avenue Therapeutics Q1 net loss $4.3M; $9.4M raised; pipeline progress on AJ201, BAER-101, IV tramadol","bullets":["Net loss $4.3M ($15.40/share) vs $7.5M ($101.57) in Q1 2023; R&D $2.4M, G&A $1.3M.","Cash $3.2M at Mar 31, up from $1.8M; additional $4.4M gross proceeds from May 2024 warrant exercise.","AJ201 topline data for Kennedy's Disease expected mid-2024; received FDA agreement on IV tramadol Phase 3 protocol.","Total $9.4M raised from warrant exercises in Jan and May 2024; 1-for-75 reverse split in April to regain Nasdaq compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-016818","json":"https://secwatch.observer/filing/0001437749-24-016818.json","markdown":"https://secwatch.observer/filing/0001437749-24-016818.md","text":"https://secwatch.observer/filing/0001437749-24-016818.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000143774924016818/0001437749-24-016818-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000143774924016818/atxi20240113_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:15:04.565565+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"12d9b2e7eb51223df495bfb187da73c695e983e9","claim":"AVENUE THERAPEUTICS, INC. reported the first quarter ended March 31, 2024 results: net income $4.3 million, or $15.40 per share, EPS $15.40 per share.","evidence_excerpt":"Net loss attributable to common stockholders for the first quarter of 2024 was $4.3 million, or $15.40 per share, compared to a net loss of $7.5 million, or $101.57 per share, for the first quarter of 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1644963/000143774924016818/0001437749-24-016818-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"$4.3 million, or $15.40 per share"},{"label":"EPS","value":"$15.40 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}